AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Ando, Fumiaki ^a   Mori, Shuichi ^a   Yui, Naofumi ^a   Morimoto, Tetsuji ^b   Nomura, Naohiro ^a   Sohara, Eisei ^a   Rai, Tatemitsu ^a   Sasaki, Sei ^a   Kondo, Yoshiaki ^c   Kagechika, Hiroyuki ^a   Uchida, Shinichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIAMINO 4,4' DIHYDROXYDIPHENYLMETHANE; 3,4,3',4' TETRAHYDROXYBENZOPHENONE; 4 BENZYLCHATECHOL; AQUAPORIN 2; BETA ACTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IIALPHA; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IIBETA; DESMOPRESSIN; FMP API 1; FMP API 1 27; FMP API 1 28; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HT 31; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; TROPONIN I; UNCLASSIFIED DRUG; UVOMORULIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; AQP2 PROTEIN, MOUSE; ARGIPRESSIN; BENZAZEPINE DERIVATIVE; BENZHYDRYL DERIVATIVE; CYCLIC AMP; PHENOL DERIVATIVE; PROTEIN BINDING; TOLVAPTAN; VASOPRESSIN RECEPTOR; WATER;

DIABETES; ENDOCRINE DISRUPTOR; ENZYME ACTIVITY; HORMONE; INHIBITION; MUTATION; NUMERICAL MODEL; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEDTIME DOSAGE; COLLECTING TUBULE CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; KIDNEY CORTEX; MALE; MOLECULAR WEIGHT; MOUSE; MPKCCD CELL LINE; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; URINE OSMOLALITY; AGONISTS; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OSMOLARITY; PATHOLOGY; TRANSFORMED CELL LINE;

A KINASE ANCHOR PROTEINS; AMINO ACID SEQUENCE; ANIMALS; AQUAPORIN 2; ARGININE VASOPRESSIN; BENZAZEPINES; BENZHYDRYL COMPOUNDS; CELL LINE, TRANSFORMED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES INSIPIDUS, NEPHROGENIC; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY TUBULES, COLLECTING; MALE; MICE, INBRED C57BL; OSMOLAR CONCENTRATION; PHENOLS; PROTEIN BINDING; RECEPTORS, VASOPRESSIN; WATER;

EID: 85045508879     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-03771-2     Document Type: Article

References (48)

1. Wesche, D., Deen, P. M. & Knoers, N. V. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr. Nephrol. 27, 2183-2204 (2012).
2. Moeller, H. B., Rittig, S. & Fenton, R. A. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr. Rev. 34, 278-301 (2013).
3. Fujimoto, M. et al. Clinical overview of nephrogenic diabetes insipidus based on a nationwide survey in Japan. Yonago. Acta Med. 57, 85-91 (2014).
4. Brown, D., Hasler, U., Nunes, P., Bouley, R. & Lu, H. A. Phosphorylation events and the modulation of aquaporin 2 cell surface expression. Curr. Opin. Nephrol. Hypertens. 17, 491-498 (2008).
5. Fushimi, K., Sasaki, S. & Marumo, F. Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J. Biol. Chem. 272, 14800-14804 (1997).
6. Yui, N., Sasaki, S. & Uchida, S. Aquaporin-2 Ser-261 phosphorylation is regulated in combination with Ser-256 and Ser-269 phosphorylation. Biochem. Biophys. Res. Commun. 482, 524-529 (2017).
7. Hoffert, J. D. et al. Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J. Biol. Chem. 283, 24617-24627 (2008).
8. Xie, L. et al. Quantitative analysis of aquaporin-2 phosphorylation. Am. J. Physiol. Ren. Physiol. 298, F1018-F1023 (2010).
9. Moeller, H. B., Aroankins, T. S., Slengerik-Hansen, J., Pisitkun, T. & Fenton, R. A. Phosphorylation and ubiquitylation are opposing processes that regulate endocytosis of the water channel aquaporin-2. J. Cell Sci. 127, 3174-3183 (2014).
10. Yui, N., Ando, F., Sasaki, S. & Uchida, S. Ser-261 phospho-regulation is involved in pS256 and pS269-mediated aquaporin-2 apical translocation. Biochem. Biophys. Res. Commun. 490, 1039-1044 (2017).
11. Sasaki, S., Chiga, M., Kikuchi, E., Rai, T. & Uchida, S. Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2. Clin. Exp. Nephrol. 17, 338-344 (2013).
12. Morello, J. P. & Bichet, D. G. Nephrogenic diabetes insipidus. Annu. Rev. Physiol. 63, 607-630 (2001).
13. Li, J. H. et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J. Clin. Invest. 119, 3115-3126 (2009).
14. Bouley, R. et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J. Am. Soc. Nephrol. 22, 59-72 (2011).
15. Li, C. et al. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am. J. Physiol. Ren. Physiol. 300, F1255-F1261 (2011).
16. Olesen, E. T., Rützler, M. R., Moeller, H. B., Praetorius, H. A. & Fenton, R. A. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA 108, 12949-12954 (2011).
17. Procino, G. et al. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice. Kidney Int. 86, 127-138 (2014).
18. Wong, W. & Scott, J. D. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 5, 959-970 (2004).
19. Jo, I. et al. AQP2 is a substrate for endogenous PP2B activity within an inner medullary AKAP-signaling complex. Am. J. Physiol. Ren. Physiol. 281, F958-F965 (2001).
20. Henn, V. et al. Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J. Biol. Chem. 279, 26654-26665 (2004).
21. Okutsu, R. et al. AKAP220 colocalizes with AQP2 in the inner medullary collecting ducts. Kidney Int. 74, 1429-1433 (2008).
22. Carr, D. W., Hausken, Z. E., Fraser, I. D., Stofko-Hahn, R. E. & Scott, J. D. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RIIbinding domain. J. Biol. Chem. 267, 13376-13382 (1992).
23. Vijayaraghavan, S., Goueli, S. A., Davey, M. P. & Carr, D. W. Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility. J. Biol. Chem. 272, 4747-4752 (1997).
24. Ma, L. et al. Ht31, a protein kinase A anchoring inhibitor, induces robust cholesterol efflux and reverses macrophage foam cell formation through ATPbinding cassette transporter A1. J. Biol. Chem. 286, 3370-3378 (2011).
25. Bens, M. et al. Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line. J. Am. Soc. Nephrol. 10, 923-934 (1999).
26. Hasler, U. et al. Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J. Biol. Chem. 277, 10379-10386 (2002).
27. Schillace, R. V. et al. A-kinase anchoring in dendritic cells is required for antigen presentation. PLoS ONE 4, e4807 (2009).
28. Motawea, H. K. et al. Delocalization of endogenous A-kinase antagonizes Rap1-Rho-α2C-adrenoceptor signaling in human microvascular smooth muscle cells. J. Cytol. Mol. Biol. 1, 9 (2014).
29. Müsch, A. et al. Mammalian homolog of Drosophila tumor suppressor lethal (2) giant larvae interacts with basolateral exocytic machinery in Madin-Darby canine kidney cells. Mol. Biol. Cell 13, 158-168 (2002).
30. Smith, F. D. et al. Local protein kinase A action proceeds through intact holoenzymes. Science 356, 1288-1293 (2017).
31. Moeller, H. B., Knepper, M. A. & Fenton, R. A. Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells. Kidney Int. 75, 295-303 (2009).
32. Ando, F. et al. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway. Nat. Commun. 7, 13636 (2016).
33. Vukićević, T., Schulz, M., Faust, D. & Klussmann, E. The trafficking of the water channel aquaporin-2 in renal principal cells-a potential target for pharmacological intervention in cardiovascular diseases. Front. Pharmacol. 7, 23 (2016).
34. Christian, F. et al. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286, 9079-9096 (2011).
35. Miranda, C. A., Lee, J. W., Chou, C. L. & Knepper, M. A. Tolvaptan as a tool in renal physiology. Am. J. Physiol. Ren. Physiol. 306, F359-F366 (2014).
36. Kapiloff, M. S., Rigatti, M. & Dodge-Kafka, K. L. Architectural and functional roles of A kinase-anchoring proteins in cAMP microdomains. J. Gen. Physiol. 143, 9-15 (2014).
37. Gold, M. G. et al. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol. Cell 24, 383-395 (2006).
38. Herberg, F. W., Maleszka, A., Eide, T., Vossebein, L. & Tasken, K. Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding. J. Mol. Biol. 298, 329-339 (2000).
39. Pidoux, G. & Taskén, K. Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. J. Mol. Endocrinol. 44, 271-284 (2010).
40. Lee, J. W., Chou, C. L. & Knepper, M. A. Deep sequencing in microdissected renal tubules identifies nephron segment-specific transcriptomes. J. Am. Soc. Nephrol. 26, 2669-2677 (2015).
41. Rinschen, M. M. et al. Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc. Natl Acad. Sci. USA 107, 3882-3887 (2010).
42. Bradford, D. et al. Use of LC-MS/MS and Bayes' theorem to identify protein kinases that phosphorylate aquaporin-2 at Ser256. Am. J. Physiol. Cell Physiol. 307, C123-C139 (2014).
43. Yui, N. et al. Basolateral targeting and microtubule-dependent transcytosis of the aquaporin-2 water channel. Am. J. Physiol. Cell Physiol. 304, C38-C48 (2013).
44. Nomura, N. et al. High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration. Am. J. Physiol. Cell Physiol. 307, C597-C605 (2014).
45. Quigley, R., Chakravarty, S. & Baum, M. Antidiuretic hormone resistance in the neonatal cortical collecting tubule is mediated in part by elevated phosphodiesterase activity. Am. J. Physiol. Ren. Physiol. 286, F317-F322 (2004).
46. Schnermann, J. et al. Defective proximal tubular fluid reabsorption in transgenic aquaporin-1 null mice. Proc. Natl Acad. Sci. USA 95, 9660-9664 (1998).
47. Shi, D. et al. Bromophenols as inhibitors of protein tyrosine phosphatase 1B with antidiabetic properties. Bioorg. Med. Chem. Lett. 22, 2827-2832 (2012).
48. Torres-Quesada, O., Mayrhofer, J. E. & Stefan, E. The many faces of compartmentalized PKA signalosomes. Cell. Signal. 37, 1-11 (2017).